X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DR. DATSONS LABS NATCO PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 23.5 -10.9 - View Chart
P/BV x 17.8 0.2 10,972.8% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
DR. DATSONS LABS
Mar-14
NATCO PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs877126 698.2%   
Low Rs42431 1,370.6%   
Sales per share (Unadj.) Rs223.4133.0 168.0%  
Earnings per share (Unadj.) Rs31.10.2 20,491.6%  
Cash flow per share (Unadj.) Rs40.36.6 609.5%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.5128.8 170.4%  
Shares outstanding (eoy) m33.0731.66 104.5%   
Bonus/Rights/Conversions PAFCCB-  
Price / Sales ratio x2.90.6 494.6%   
Avg P/E ratio x20.9516.1 4.1%  
P/CF ratio (eoy) x16.111.8 136.3%  
Price / Book Value ratio x3.00.6 487.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5042,477 868.0%   
No. of employees `000NANA-   
Total wages/salary Rs m1,12856 2,013.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,3894,211 175.5%  
Other income Rs m16779 212.3%   
Total revenues Rs m7,5564,289 176.2%   
Gross profit Rs m1,793569 315.4%  
Depreciation Rs m304204 148.9%   
Interest Rs m366430 85.1%   
Profit before tax Rs m1,29013 10,155.9%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3096 5,060.7%   
Profit after tax Rs m1,0275 21,404.2%  
Gross profit margin %24.313.5 179.7%  
Effective tax rate %23.948.0 49.8%   
Net profit margin %13.90.1 12,197.0%  
BALANCE SHEET DATA
Current assets Rs m3,6816,852 53.7%   
Current liabilities Rs m3,1236,711 46.5%   
Net working cap to sales %7.63.3 225.7%  
Current ratio x1.21.0 115.5%  
Inventory Days Days89161 55.6%  
Debtors Days Days59318 18.4%  
Net fixed assets Rs m7,6853,673 209.2%   
Share capital Rs m331317 104.5%   
"Free" reserves Rs m6,6703,761 177.3%   
Net worth Rs m7,2594,078 178.0%   
Long term debt Rs m9551,671 57.2%   
Total assets Rs m11,95712,633 94.7%  
Interest coverage x4.51.0 439.2%   
Debt to equity ratio x0.10.4 32.1%  
Sales to assets ratio x0.60.3 185.4%   
Return on assets %11.73.4 338.5%  
Return on equity %14.20.1 12,023.4%  
Return on capital %20.77.7 270.1%  
Exports to sales %39.422.9 171.9%   
Imports to sales %5.714.3 39.9%   
Exports (fob) Rs m2,908964 301.6%   
Imports (cif) Rs m421602 70.0%   
Fx inflow Rs m3,445964 357.4%   
Fx outflow Rs m703607 115.8%   
Net fx Rs m2,743357 768.5%   
CASH FLOW
From Operations Rs m1,4401,345 107.1%  
From Investments Rs m-1,089-2,256 48.3%  
From Financial Activity Rs m-353-1,200 29.4%  
Net Cashflow Rs m-1-2,111 0.1%  

Share Holding

Indian Promoters % 52.0 4.5 1,148.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.0 -  
FIIs % 16.6 1.4 1,231.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 94.1 27.6%  
Shareholders   25,395 20,807 122.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  WOCKHARDT LTD.  VENUS REMEDIES  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - IPCA LABS COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS